Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
Metagenomi (NASDAQ:MGX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference [Yahoo! Finance]
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
Metagenomi (NASDAQ:MGX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.